Tag: Renibus

Renibus Reports Positive Final Results from Phase 2 Study of RBT-1, a First-in-Class Preconditioning Agent for Patients Undergoing Cardiothoracic Surgery, at the American Association for Thoracic Surgery (AATS) Meeting

Coronary/Structural Heart by 0 comments

RBT-1 achieved the primary biomarker endpoint, as well as several key clinical outcome endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery– RBT-1 as a preconditioning agent has the potential to provide patient benefits […]

Continue Reading →

Renibus Therapeutics Raises $33 Million Bridge Financing to Advance its Portfolio of Cardiorenal Product Candidates

Financial by 0 comments

SOUTHLAKE, Texas, Nov. 14, 2022 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biotechnology company developing breakthrough products for cardiorenal diseases, today announced a $33 million bridge financing consisting of a $23 million SAFE (Simple Agreement for Future Equity) offering and $10 million pursuant to the first tranche […]

Continue Reading →